Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopregnanolone in Parkinson's Disease
NCT06263010Phase 1Completed
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brexanolone in Parkinson's disease (PD) (2 arms). Primary endpoint: Study completion at 13 weeks. Started Jan 2024; status: completed.
02
Drugs
brexanolone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06263010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263010.